Edesa Biotech Statistics
Total Valuation
Edesa Biotech has a market cap or net worth of $13.09 million. The enterprise value is $728,335.
Important Dates
The next estimated earnings date is Friday, December 12, 2025, after market close.
| Earnings Date | Dec 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Edesa Biotech has 7.04 million shares outstanding. The number of shares has increased by 50.37% in one year.
| Current Share Class | 7.04M |
| Shares Outstanding | 7.04M |
| Shares Change (YoY) | +50.37% |
| Shares Change (QoQ) | +32.36% |
| Owned by Insiders (%) | 10.16% |
| Owned by Institutions (%) | 1.57% |
| Float | 4.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.66 |
| P/TBV Ratio | 4.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.97
| Current Ratio | 18.97 |
| Quick Ratio | 18.80 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -69.64% and return on invested capital (ROIC) is -47.29%.
| Return on Equity (ROE) | -69.64% |
| Return on Assets (ROA) | -40.22% |
| Return on Invested Capital (ROIC) | -47.29% |
| Return on Capital Employed (ROCE) | -45.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$369,951 |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Edesa Biotech has paid $800 in taxes.
| Income Tax | 800 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.29% in the last 52 weeks. The beta is 0.07, so Edesa Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.07 |
| 52-Week Price Change | -45.29% |
| 50-Day Moving Average | 2.46 |
| 200-Day Moving Average | 2.25 |
| Relative Strength Index (RSI) | 30.71 |
| Average Volume (20 Days) | 898,720 |
Short Selling Information
The latest short interest is 9,328, so 0.13% of the outstanding shares have been sold short.
| Short Interest | 9,328 |
| Short Previous Month | 6,981 |
| Short % of Shares Out | 0.13% |
| Short % of Float | 0.22% |
| Short Ratio (days to cover) | 0.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.45M |
| Pretax Income | -5.92M |
| Net Income | -5.92M |
| EBITDA | -6.38M |
| EBIT | -6.45M |
| Earnings Per Share (EPS) | -$1.25 |
Full Income Statement Balance Sheet
The company has $12.36 million in cash and n/a in debt, giving a net cash position of $12.36 million or $1.76 per share.
| Cash & Cash Equivalents | 12.36M |
| Total Debt | n/a |
| Net Cash | 12.36M |
| Net Cash Per Share | $1.76 |
| Equity (Book Value) | 14.13M |
| Book Value Per Share | 0.70 |
| Working Capital | 12.09M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -6.57M |
| Capital Expenditures | n/a |
| Free Cash Flow | -6.57M |
| FCF Per Share | -$0.93 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Edesa Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -50.37% |
| Shareholder Yield | -50.37% |
| Earnings Yield | -45.22% |
| FCF Yield | -50.18% |
Analyst Forecast
The average price target for Edesa Biotech is $13.00, which is 598.93% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.00 |
| Price Target Difference | 598.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 11, 2023. It was a reverse split with a ratio of 1:7.
| Last Split Date | Oct 11, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |